Widmann Financial Services Inc. Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Widmann Financial Services Inc. grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 12.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,611 shares of the company’s stock after purchasing an additional 400 shares during the period. Widmann Financial Services Inc.’s holdings in AstraZeneca were worth $281,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. CANADA LIFE ASSURANCE Co lifted its holdings in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares in the last quarter. Tidal Investments LLC bought a new stake in shares of AstraZeneca during the first quarter valued at approximately $327,000. Cetera Investment Advisers boosted its holdings in shares of AstraZeneca by 249.0% in the first quarter. Cetera Investment Advisers now owns 207,497 shares of the company’s stock valued at $14,058,000 after purchasing an additional 148,042 shares during the period. Cetera Advisors LLC grew its stake in AstraZeneca by 124.5% in the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after purchasing an additional 54,488 shares in the last quarter. Finally, Boston Partners purchased a new position in AstraZeneca during the 1st quarter worth $309,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 0.6 %

NASDAQ:AZN opened at $67.62 on Friday. The company’s 50-day simple moving average is $72.27 and its 200-day simple moving average is $77.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock has a market capitalization of $209.66 billion, a P/E ratio of 32.35, a P/E/G ratio of 1.23 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the firm earned $0.87 earnings per share. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. On average, equities analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen raised their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.